VANCOUVER, BC – Genome BC has awarded Qu Biologics Inc. $240,000 in funding to support a Phase 2a clinical trial of Qu Biologics’ QBECO Site Specific Immunomodulators (SSI’s) for the treatment of moderate-to-severe ulcerative colitis (UC).
In this study, Qu Biologics will investigate the safety, efficacy and immunologic mechanism of action of QBECO SSI and assess the correlation between genetic polymorphisms associated with UC, the microbiome, and QBECO SSI efficacy. Genome BC is supporting this research through its Strategic Opportunities Fund for Industry (SOFi) program. The SOFi program seeks to accelerate commercial potential with local companies and facilitate collaboration with industry.
The study, which is already underway, will also investigate the effect of QBECO SSI treatment on the composition of the fecal microbiome, whether the microbiome impacts the immunologic and therapeutic response, and if genetic factors affect the immunologic and therapeutic response to QBECO SSI treatment.
The ulcerative colitis study has completed enrollment of the first group of participants. Enrollment of a second group of participants into the clinical trial is expected to begin in late 2016.